PharmaShots | Incisive News in 3 Shots

Subscribe Now

Neck Squamous Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic or Unresectable Recurrent Head and Neck Squ...

November 20, 2019

Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and...

May 31, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us